Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
News|Videos|March 2, 2026
6 Hepatology Headlines You Missed in February 2026
Author(s)Abigail Brooks, MA
Fact checked by: Ryan Livingston
Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.
Advertisement
Advertisement
February 2026 spotlighted a wave of innovation in genetic and translational hepatology, particularly in alpha-1 antitrypsin deficiency (AATD). Interim data for YOLT-202 demonstrated that a single in vivo base-editing dose could meaningfully increase functional AAT levels, while TSRA-196 earned both Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA), reinforcing growing regulatory support for one-time gene-editing strategies aimed at correcting the underlying PiZZ mutation.
Related to this article
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement